Anixa is a biotechnology company focused on harnessing the body’s immune system in the fight against cancer. By using the body’s immune system, Anixa is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.
Anixa's therapeutics portfolio includes a cancer immunotherapy program, which uses chimeric endocrine receptor t-cell (CER-T) technology, a novel type of CAR-T, and a cancer vaccine technology focused specifically on triple negative breast cancer (TNBC), the most lethal form of the disease.
Anixa's diagnostics portfolio includes the Cchek™ liquid biopsy technology, a series of inexpensive non-invasive blood tests for early detection of solid tumors based on the body's immune response to the presence of a malignancy.
Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Strong Leadership Backed by Success
Our management team has had many successes, especially in connection with starting, building and investing in technology related companies.
Sign up for email Updates
Be The First to Receive Breaking NewsSign Up Now